title: Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis.
abstract: BACKGROUND
  Oral mucositis is a frequent problem after high-dose methotrexate (HD-MTX), impairing patient's quality of life, leading to higher rates of infections and delaying subsequent chemotherapy. This report describes the effect of palifermin in patients treated within the GMALL-B-ALL 2002 protocol containing HD-MTX who developed a severe mucositis in cycle A1/B1.
  
  
  METHODS
  Ten patients, all with World Health Organization grades III-IV oral mucositis in cycles A1/B1, obtained palifermin with subsequent similar or identical cycles to reduce mucositis. Thus, patients serve as their own control for efficacy of palifermin.
  
  
  RESULTS
  All 10 patients developed grades III-IV mucositis in cycles A1/B1 without palifermin, whereas only two of 10 developed grades III-IV mucositis in corresponding cycles A2/B2 with palifermin. Only four of 10 patients showed infections in the cycles with palifermin compared with 10 of 10 patients without palifermin. The duration of mucositits in patients who acquired a higher grade mucositis despite treatment with palifermin could be reduced from 12.9 days (median) without to 11 days with palifermin. The amount of i.v. opioid analgetics could be significantly reduced.
  
  
  CONCLUSIONS
  Palifermin might reduce the incidence, severeness and duration of oral mucositis in HD-MTX-based chemotherapy and may influence clinical sequelae such as infection and quality of life.
authors.affiliation: Department of Medicine, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Schmidt
authors.forename: N H
authors.initials: NH
authors.lastname: Thoennissen
authors.forename: A
authors.initials: A
authors.lastname: Rudat
authors.forename: R
authors.initials: R
authors.lastname: Bieker
authors.forename: C
authors.initials: C
authors.lastname: Schliemann
authors.forename: R M
authors.initials: RM
authors.lastname: Mesters
authors.forename: M
authors.initials: M
authors.lastname: Zühlsdorf
authors.forename: C
authors.initials: C
authors.lastname: Müller-Tidow
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D010147:Pain Measurement; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000473:pathology; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D013280:Stomatitis / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D051523:Fibroblast Growth Factor 7; D008727:Methotrexate